The domestic business has registered a single-digit growth on the huge base of last year and this was driven by robust demand across established therapies and brands
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies
Lupin is the 6th largest company in the Indian Pharmaceutical Market
The company has reported total income of Rs. 253.42 crores during the period ended June 30, 2022.
First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The WAVEsystem with the WAVEcontrol 4.0 embedded
Subscribe To Our Newsletter & Stay Updated
